HomeCompareESALY vs CHD

ESALY vs CHD: Dividend Comparison 2026

ESALY yields 31.26% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESALY wins by $272.3K in total portfolio value
10 years
ESALY
ESALY
● Live price
31.26%
Share price
$61.51
Annual div
$19.23
5Y div CAGR
7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298.7K
Annual income
$71,135.45
Full ESALY calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — ESALY vs CHD

📍 ESALY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALY
Annual income on $10K today (after 15% tax)
$2,657.23/yr
After 10yr DRIP, annual income (after tax)
$60,465.13/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, ESALY beats the other by $59,366.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALY + CHD for your $10,000?

ESALY: 50%CHD: 50%
100% CHD50/50100% ESALY
Portfolio after 10yr
$162.5K
Annual income
$36,213.97/yr
Blended yield
22.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

ESALY
No analyst data
Altman Z
5.1
Piotroski
4/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALY buys
0
CHD buys
0
No recent congressional trades found for ESALY or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALYCHD
Forward yield31.26%1.27%
Annual dividend / share$19.23$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7%23.1%
Portfolio after 10y$298.7K$26.4K
Annual income after 10y$71,135.45$1,292.51
Total dividends collected$238.7K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ESALY vs CHD ($10,000, DRIP)

YearESALY PortfolioESALY Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$14,045$3,344.99$10,856$156.32+$3.2KESALY
2$19,726$4,698.03$11,811$195.24+$7.9KESALY
3$27,705$6,598.37$12,883$244.38+$14.8KESALY
4$38,912$9,267.41$14,091$306.64+$24.8KESALY
5$54,652$13,016.06$15,463$385.88+$39.2KESALY
6$76,759$18,281.04$17,033$487.17+$59.7KESALY
7$107,808$25,675.69$18,843$617.36+$89.0KESALY
8$151,416$36,061.47$20,947$785.72+$130.5KESALY
9$212,663$50,648.29$23,419$1,004.91+$189.2KESALY
10$298,685$71,135.45$26,350$1,292.51+$272.3KESALY

ESALY vs CHD: Complete Analysis 2026

ESALYStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this ESALY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALY vs SCHDESALY vs JEPIESALY vs OESALY vs KOESALY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.